disease.' In a series of studies in children as well as in adults we have shown a high diagnostic sensitivity and specificity of combined evaluation of gliadin specific antibodies of the IgA and IgG isotypes.7-The usefulness of determination of such antibodies for the follow up of clinical recovery in coeliac patients subjected to a gluten free diet has also been shown.'" More recently, IgGl and IgG3 antigliadin antibodies have also been suggested to be closely associated with coeliac disease." Whether antigliadin antibodies in serum reflect an abnormal immune reactivity to gluten in the gut mucosa, the site of the primary lesion of the disease, is, however, not known.
The immunoglobulin production in the intestinal mucosa of patients with coeliac disease has been studied by immunohistochemical methods and by determination in supernatants from cultured mucosal biopsies. Patients with coeliac disease have been found to have increased numbers of IgA-and IgM-72 producing cells in the gut mucosa as compared with healthy controls.'-"'4 Increased numbers of IgGproducing cells have also been shown.'415 In accord with the immunohistochemical results an increased production of IgA and IgM and in one study also of IgG from cultured biopsies has been reported."" '9 The specificity of the locally produced antibodies is less well studied. Falchuk et al20 showed for six of seven patients studied before and during gluten challenge that about half of the increase of the IgA and IgM secretion from mucosal biopsies was attributed to synthesis of gliadin antibodies. Ciclitira et all9 showed increased production of antigliadin specific IgM Ten adult patients of both sexes (age range, 20-66 years) with clinical symptoms characteristic of coeliac disease were, after informed consent, subjected to duodenal biopsies, using biopsy forceps during diagnostic endoscopy.Y All patients were untreated at the time of investigation and light microscopy of biopsy specimens showed subtotal villous atrophy. Institution of a gluten free diet resulted in improvement of clinical symptoms in all patients and in nine of the subjects tested to date a significant morphological improvement of the gut mucosa was also observed.
Ten additional patients were included in the study for control purposes. These patients were undergoing routine endoscopy for the investigation of epigastric pain or diarrhoea and none of them had any evidence of small bowel disease. Biopsies, obtained after informed consent, showed normal villous structure.
The studies performed were approved by the Ethical Committee of the University of Goteborg. PREPARATION The magnitude of the antigliadin antibody response observed in this study is noteworthy and it may be compared with antigen specific peak SFC responses registered in lamina propria after oral immunisations of mice with the potent antigen cholera toxin. 24 Neither IgM nor IgG anti-gliadin SFC were consistently seen in our coeliac patients. With regard to a possible immunopathological role of local antigliadin production in gut mucosa it would seem less likely that abnormal IgG or IgM responses to gliadin with complement or Fc-receptor mediated destruction of mucosal tissues would play a primary role in the disease as previously been suggested. 23 The high titres of IgG antigliadin in serum in untreated coeliac patients or the sequential increase by time of such antibodies in serum of children with coeliac diease4 61013 might rather reflect altered intestinal permeability. The occurrence of such a systemic exposure to gliadin was suggested by the two coeliac patients showing antigliadin SFC among peripheral blood mononuclear cells. These two patients also had the highest intestinal SFC numbers.
The fact that IgA deficient individuals can develop coeliac disease18 may suggest that cell mediated immune mechanisms may be operating in coeliac disease. If an adverse response to gliadin in the gut in susceptible individuals is the cause of tissue damage this could be the result of abnormal T cell regulation of local mucosal immune responses.2 Whether such a defect is the result of a gliadin specific suppressor T cell dysfunction in coeliac patients as supported by the findings of Corazza et al,29 or is a consequence of yet other mechanisms, is not known.
The method presented here might provide a useful instrument for further study of cell mediated immunity and antibody production and its control mechanisms in the gut mucosa of patients with coeliac disease. We thank Lena Ekman, Ulla Karlsson, Ella Olofsson, and Lena Svensson for skilled technical assistance. Our thanks are also due to Dr C Ahr6n for histological evaluation of biopsy specimens. This study was supported by grants from the Swedish Medical Research Council, the Swedish Society of Medicine, the Gothenburg Medical Society, and the Ellen, Walter, and Lennart Hesselman Foundation. 
